No Data
No Data
HSBC Downgrades Biogen to Hold From Buy, Adjusts Price Target to $118 From $342
Goldman Sachs: The Q1 performance of U.S. pharmaceutical stocks is reassuring, and the Industry sentiment is slightly becoming more positive.
Goldman Sachs stated that amid cautious sentiment from investors towards the USA pharmaceutical sector before the Earnings Reports season, the performance of USA pharmaceutical companies that have reported results so far for the first quarter has not been worse than expected, and in some cases, it has even exceeded expectations.
Earnings Week Ahead: MSFT, AAPL, META, AMZN, QCOM, PFE, MA, V, PYPL, ROKU, MCD, SBUX, KO, and More
Earnings Preview: Biogen to Report Financial Results Pre-market on May 01
Express News | Needham Reiterates Hold on Biogento Hold
RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $217